XGEN Venture led a $33m Series A funding round in EpilepsyGTx.

XGEN Venture, a venture capital investor, led a $33m Series A funding round in EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies, with participation from British Business Bank and an unnamed global pharmaceutical company. "We believe that localized gene delivery offers a powerful avenue for durable and disease-modifying interventions in severe neurological disorders and are excited to support the company as EPY201 progresses toward clinical evaluation," Federica Draghi, XGEN Venture Managing Partner.